Why Hormone Therapy Is Not Recommended to Prevent Heart Disease or Dementia

The US Preventive Services Task Force gives menopausal hormone therapy a Grade D recommendation for the primary prevention of chronic conditions, meaning it recommends against starting hormones for that purpose. In its 2022 statement, published in JAMA, the Task Force concluded that using estrogen plus progestin, or estrogen alone after hysterectomy, to lower future risk of heart disease, stroke, dementia, or other chronic illness offers no net benefit. That verdict is narrow and specific. It says nothing about whether hormone therapy is a reasonable choice for treating menopausal symptoms, which the Task Force explicitly set aside as a separate question.

What a Grade D recommendation actually covers

A USPSTF grade is a statement about one clinical question, defined by a specific population, a specific intervention, and a specific goal. Here the population is postmenopausal people without symptoms who might take hormones purely to lower long-term disease risk. The Task Force issued two parallel conclusions: do not use combined estrogen and progestin for the primary prevention of chronic conditions in postmenopausal people with a uterus, and do not use estrogen alone for the same purpose in those who have had a hysterectomy. A D grade means there is at least moderate certainty that the intervention has no net benefit, or that its harms outweigh its benefits.

Read the fine print and the boundaries are explicit. The recommendation does not apply to people using hormone therapy to manage hot flashes, night sweats, or genitourinary symptoms such as vaginal dryness. It also excludes people with premature or surgically induced menopause, and it is not about treating anyone who already has the conditions in question. Prevention in a person with no symptoms is the whole of what the D grade addresses.

The evidence behind the verdict

The recommendation rests heavily on the Women's Health Initiative, the large randomized trials that tested exactly the preventive hypothesis many clinicians once believed. Before those trials, observational data had suggested hormones might protect the heart. The randomized results did not confirm it. As the National Heart, Lung, and Blood Institute summarizes, estrogen plus progestin after menopause raised the risk of heart disease, stroke, blood clots, breast cancer, and dementia, while estrogen alone raised the risk of stroke and blood clots. The 2022 JAMA statement reports the same pattern: no meaningful reduction in coronary heart disease, increased stroke and venous clot risk, and, in the memory substudy of older women, increased probable dementia with combined therapy.

Estrogen alone, given to women who had a hysterectomy, carried a somewhat different balance, with increased stroke and clot risk but without the same breast cancer signal, and in extended follow-up a lower breast cancer risk. Both regimens did reduce fractures, a genuine benefit. The Task Force weighed that fracture reduction against the documented harms and judged that, for the specific goal of preventing chronic disease in people without symptoms, the trade was not worth making. No net benefit was the operative phrase.

Why the prevention framing is the crux

A medicine can be wrong for one job and reasonable for another. Aspirin is a familiar example: once recommended broadly to prevent first heart attacks, it has been steadily narrowed as bleeding risks were weighed against a shrinking benefit. The useful question is rarely whether a drug is good or bad in the abstract. It is good or bad for whom, toward what end, and at what stage of life. Hormone therapy studied as a preventive medication across a broad postmenopausal population answers one version of that question. It does not answer the version a 51-year-old with disruptive hot flashes is actually asking.

Why symptom relief is a separate question

Menopausal symptom treatment turns on a different calculation, with a different population and a different time horizon. Symptomatic women tend to be younger and closer to the menopausal transition, the benefit being sought is relief that is often immediate and measurable, and the duration of use is typically limited. Professional societies focused on menopause evaluate that question on its own terms, weighing an individual's symptom burden, age, time since menopause, and personal risk factors for clots, stroke, and breast cancer. Those evaluations can reach conclusions that look different from a blanket D grade, without contradicting it, because they answer a different question.

Conflating the two is the most common error in how this recommendation gets reported. A headline that reads "hormones do not prevent disease" is accurate. A headline that reads "hormones are dangerous and no one should take them" is not what the evidence says. The D grade is a verdict on a preventive strategy, not a global judgment on a class of medicines.

How to read a recommendation like this

Two habits help. First, find the population and the endpoint before reacting to the grade. A recommendation aimed at asymptomatic prevention tells you little about symptomatic treatment, and the reverse holds too. Second, notice the difference between what a label or guideline legally states and what people assume it means. A regulatory label describes what has been demonstrated for a defined use; it is not a personalized instruction, and it does not automatically transfer to every situation a patient faces.

The strength of the USPSTF process is precisely its narrowness. By refusing to stretch its evidence review beyond the question the trials actually tested, it produces a conclusion you can trust for that question and a clear signal that other questions need their own analysis. For anyone weighing menopausal hormone therapy, the practical takeaway is that "should I take this to prevent dementia?" and "should I take this to live better through menopause?" are two conversations, and the first should not be allowed to answer the second.

This article is educational and is not medical advice; decisions about hormone therapy belong in a conversation with a qualified clinician who knows the individual.